Last10K.com

Brainstorm Cell Therapeutics Inc. (BCLI) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Brainstorm Cell Therapeutics Inc.

CIK: 1137883 Ticker: BCLI
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2018
Mar. 28, 2019
Jun. 30, 2018
Document and Entity Information [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2018  
Document Fiscal Year Focus2018  
Document Fiscal Period FocusFY  
Entity Registrant NameBRAINSTORM CELL THERAPEUTICS INC.  
Entity Central Index Key0001137883  
Current Fiscal Year End Date--12-31  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Public Float  $ 71,031,012
Trading SymbolBCLI  
Entity Common Stock, Shares Outstanding 29,490,610 
Entity Shell Companyfalse  
Entity Emerging Growth Companyfalse  
Entity Small Businesstrue  

View differences made from one year to another to evaluate Brainstorm Cell Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Brainstorm Cell Therapeutics Inc..

Continue

Assess how Brainstorm Cell Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Brainstorm Cell Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Shares
Geography
Other
Inside Brainstorm Cell Therapeutics Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Statements Of Changes In Stockholders' Equity
Statements Of Comprehensive Loss
Accounts Receivable
Accounts Receivable (Details)
Accounts Receivable (Tables)
Commitments And Contingencies
Commitments And Contingencies (Details Textual)
Commitments And Contingencies (Details)
Commitments And Contingencies (Tables)
Deferred Grant Income
Deferred Grant Income (Details Textual)
General
Prepaid Expenses
Prepaid Expenses (Details Textual)
Property And Equipment
Property And Equipment (Details Textual)
Property And Equipment (Details)
Property And Equipment (Tables)
Research And Development, Net
Research And Development, Net (Details)
Research And Development, Net (Tables)
Research And License Agreement
Research And License Agreement (Details Textual)
Short Term Deposits
Short Term Deposits (Details Textual)
Significant Accounting Policies
Significant Accounting Policies (Details Textual)
Significant Accounting Policies (Details)
Significant Accounting Policies (Policies)
Significant Accounting Policies (Tables)
Stock Capital
Stock Capital (Details 1)
Stock Capital (Details 2)
Stock Capital (Details 3)
Stock Capital (Details 4)
Stock Capital (Details 5)
Stock Capital (Details 6)
Stock Capital (Details Textual)
Stock Capital (Details)
Stock Capital (Tables)
Subsequent Events
Subsequent Events (Details Textual)
Taxes On Income
Taxes On Income (Details 1)
Taxes On Income (Details Textual)
Taxes On Income (Details)
Taxes On Income (Tables)
Transactions With Related Parties
Ticker: BCLI
CIK: 1137883
Form Type: 10-K Annual Report
Accession Number: 0001144204-19-017041
Submitted to the SEC: Fri Mar 29 2019 1:01:44 PM EST
Accepted by the SEC: Fri Mar 29 2019
Period: Monday, December 31, 2018
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bcli/0001144204-19-017041.htm